Imris Receives Regulatory Approval to Sell its Medical Systems in South Korea

Winnipeg-based Imris Inc. announced that it has gained regulatory approval from the Korea Food & Drug Administration permitting the company to immediately begin marketing its 1.5 Tesla and 3.0 Tesla IMRISneuro systems in South Korea. Imris provides image guided therapy solutions which feature fully integrated surgical and interventional suites that incorporate magnetic resonance, fluoroscopy and computed tomography to deliver on demand imaging during procedures. The company’s systems serve the neurosurgical, cardiovascular and neurovascular markets.